Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review
About this item
Full title
Author / Creator
Publisher
New York: Elsevier Inc
Journal title
Language
English
Formats
Publication information
Publisher
New York: Elsevier Inc
Subjects
More information
Scope and Contents
Contents
Regadenoson is a selective A2A adenosine receptor agonist that has been approved as a vasodilator stress agent with single-photon emission-computed tomography (SPECT) myocardial perfusion imaging (MPI). Since its approval by the Food and Drug Administration (FDA) in 2008, it has become the most commonly used pharmacologic stress agent with SPECT-MP...
Alternative Titles
Full title
Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_1993520369
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1993520369
Other Identifiers
ISSN
1071-3581
E-ISSN
1532-6551
DOI
10.1007/s12350-017-0960-6
